Mental Health Center Sofia EOOD

Running trials

• Recruiting

  Randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of Roluperidone in adults with negative symptoms of schizophrenia

  2026-525925-19-00· Phase 3· Source

• Not yet recruiting

  Evaluation of the efficacy of Trazodone in improving emotional blunting symptoms in Patients with Major Depressive Disorder

  2025-523267-38-00· Phase 4· Source

• Recruiting

  DT-101 in Adults with Major Depressive Disorder

  2025-522784-15-00· Phase 2· Source

• Recruiting

  A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Phase 3· Source

• Enrolling by invitation

  An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

  NCT07161700· Phase 2· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

  NCT07065240· Phase 2· Source

• Recruiting

  Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

  NCT06830044· Phase 3· Source

• Recruiting

  Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  NCT05850689· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression6 recruiting
• Alzheimer disease2 recruiting
• Schizophrenia1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open- labeled Long-term Extension Treatment with Aticaprant

  2024-511557-21-00· Phase 3· Source

• Completed

  A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.

  2023-508163-74-00· Phase 3· Source

• Completed

  A 52-week, Open-label Trial of CVL-231 in Adult Participants With Schizophrenia

  NCT05443724· Phase 2· Source

• Terminated

  A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

  NCT05227209· Phase 3· Source

• Completed

  An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05304767· Phase 3· Source

• Completed

  Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

  NCT05110157· Phase 3· Source

• Completed

  A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05145413· Phase 3· Source